Friday, March 31, 2023
Read Overview
Supported by independent educational grants from
Ascentage Pharma
AstraZeneca Pharmaceuticals LP
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Novartis Oncology
Regeneron Pharmaceuticals, Inc.
Seagen, Inc.
Steering Committee Chair
Professor and Chair
Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Member
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Steering Committee Member
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Steering Committee Member
Deputy Chair
Section Chief, Indolent Lymphoma and New Drug Development
Director, Lymphoma Outcomes Database
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Member
Chief, Hematology/Oncology Division
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska
Steering Committee Member
Professor of Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Steering Committee Member
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Member
Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Member
Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Member
Professor of Medicine
University of California Irvine School of Medicine
Associate Director, Clinical Science
Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research
Chao Family Endowed Chair for Cancer Clinical Science
Orange, California
Steering Committee Member
Professor of Medicine
Director, Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Steering Committee Chair
Hagop M. Kantarjian, MD, has no relevant financial relationships.
Steering Committee Member
The opinions expressed are those of Dr Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Lonial's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Janssen; Novartis; Takeda
Research funding from: Bristol Myers Squibb Company; Janssen; Novartis; Takeda
Owns stock (publicly traded) in: TG Therapeutics, Inc.
Other: Board of Directors for: TG Therapeutics, Inc.
Steering Committee Member
Has no relevant financial relationships.
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: ADC Therapeutics; Bristol Myers Squibb Company; Caribou Biosciences; Epizyme; Genentech; Gilead Sciences, Inc.; Janssen; Kite Pharma, Inc.; MorphoSys; Novartis; Roche; SIRPant Immunotherapeutics; Takeda
Research funding from: Bristol Myers Squibb Company; Caribou Biosciences; Epizyme; Genentech; Gilead Sciences, Inc.; Janssen; Kite Pharma, Inc.; Novartis; Roche; Takeda
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Daiichi Sankyo, Inc.; Genentech; Lilly; Novartis; Seagen Inc.
Research funding from: Bristol Myers Squibb Company; Epizyme; Loxo Oncology; Novartis
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Diagnostica Stago, Inc.
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Agios Pharmaceuticals/Servier; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Genentech; Genmab; Novartis; Notable Labs; Takeda
Research funding from: AbbVie, Inc.; Agios Pharmaceuticals/Servier; Astex Pharmaceuticals; Bristol Myers Squibb Company; Calithera Biosciences; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Loxo Oncology
Stock options from: Notable Labs
Steering Committee Member
Has the following relevant financial relationships:
Research funding from: AbbVie, Inc.; APR Applied Pharma Research s.a.; Astex Pharmaceuticals; Bristol Myers Squibb Company; Curis, Inc.; Genentech; Gilead Sciences, Inc.; Novartis
Steering Committee Member
Has no relevant financial relationships.
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Alexion Pharmaceuticals, Inc.; Amgen, Inc.; Aptose Biosciences Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Autolus Therapeutics; Bristol Myers Squibb Company; Celgene Corporation; DynaMed; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Johnson & Johnson; Juno Therapeutics, Inc.; Lilly; MEI Pharma; Merck; NOVA; Pfizer, Inc.; Pharmacyclics, Inc.; TG Therapeutics, Inc.; Vaniam Group; Verastem, Inc.; Vida Ventures
Research funding from: Acerta; Alliance; BeiGene (Beijing) Co., Ltd.; Caribou Biosciences; Gilead Sciences, Inc.; Kite Pharma, Inc.; Loxo Oncology; Mustang Bio, Inc.; Nurix; Pfizer, Inc.; Pharmacyclics, Inc.; Regeneron Pharmaceuticals, Inc.; TG Therapeutics, Inc.
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: CTI Biopharma Corp.; Incyte Corporation; PharmaEssentia; Novartis; Sierra Oncology, Inc.
Research funding from: AstraZeneca Pharmaceutials LP; Blueprint Medicines; Celgene Corporation; CTI BioPharma Corp.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Italfarmaco S.p.A.; Novartis; NS Pharma, Inc.; PharmaEssentia; Protagonist Therapeutics; Roche; Sierra Oncology, Inc.
